logo
logo
OrthoPediatrics Corp.

OrthoPediatrics Corp.

NASDAQ•KIDS
CEO: Mr. Mark C. Throdahl
セクター: Healthcare
業種: Medical - Devices
上場日: 2017-10-13
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
連絡先情報
2850 Frontier Drive, Warsaw, IN, 46582, United States
574-268-6379
www.orthopediatrics.com
時価総額
$419.29M
PER (TTM)
-8.6
31.5
配当利回り
--
52週高値
$26.40
52週安値
$15.28
52週レンジ
13%
順位65Top 96.0%
1.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$61.25M+12.23%
直近4四半期の推移

EPS

-$0.50+47.06%
直近4四半期の推移

フリーCF

-$3.42M-70.67%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Net revenue reached $174.7M for nine months, up 15%, driven by Trauma/Deformity and Scoliosis sales.
Financing Secured Company drew $25.0M from the delayed draw term loan facility on June 27, 2025, enhancing liquidity.
Acquisition Integration Continues Multiple O&P clinics acquired through September 30, 2025, for total consideration of approximately $6.02M.
Cash Position Maintained Cash, equivalents, and restricted cash totaled $18.9M as of September 30, 2025, supporting operations.

リスク要因

Net Loss Widened Nine-month net loss increased 36% to $(29.5M) due to rising operating expenses and restructuring costs.
Goodwill Impairment Recorded Recorded $1.9M goodwill impairment charge following the decision to exit the Telos regulatory consulting business.
Operating Costs Increased Total operating expenses rose 18.4% to $158.6M for nine months, driven by commissions and personnel costs.
Trade Policy Uncertainty Subject to risks from international trade changes, including tariffs and geopolitical shifts impacting product costs.

見通し

Strategic Market Expansion Plans include strengthening U.S. and international markets via infrastructure investment and expanding product offerings.
Cash Preservation Strategy Ongoing efforts include settling MedTech cash payments via unregistered common stock issuance instead of cash.
Liquidity Forecast Positive Management believes current cash balance is sufficient to maintain operations for more than the next twelve months.
Focus on Core Market Continue exclusive focus on pediatric orthopedic trauma, deformity correction, and sports medicine product offerings.

同業比較

売上高 (TTM)

Enhabit, Inc.EHAB
$1.05B
+1.0%
Varex Imaging CorporationVREX
$854.40M
+4.1%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

粗利益率 (最新四半期)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
RxSight, Inc.RXST
79.9%
+24.3pp
Treace Medical Concepts, Inc.TMCI
79.1%
-1.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CGEM$690.60M-3.2-41.6%0.2%
AVNS$685.14M-1.5-58.2%12.5%
SRDX$614.51M-34.8-15.6%19.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
5.2%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月3日
|
EPS:-$0.37
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月29日|
    売上高: $61.25M+12.2%
    |
    EPS: $-0.50+47.1%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $61.08M+15.7%
    |
    EPS: $-0.30+15.4%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $52.41M+17.3%
    |
    EPS: $-0.46+35.3%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月5日|
    売上高: $204.73M+37.6%
    |
    EPS: $-1.64-78.3%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $54.57M+36.5%
    |
    EPS: $-0.34+70.0%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $52.80M+33.5%
    |
    EPS: $-0.26+100.0%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月7日|
    売上高: $44.69M+41.5%
    |
    EPS: $-0.34+13.3%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月8日|
    売上高: $148.73M+21.6%
    |
    EPS: $-0.92-1643.6%
    予想を下回る